OpenAI’s Post

When is AI alone adequate for answering scientific questions? It depends. A multi-institutional team led by Paul Adams at Berkeley Lab and Tom Terwilliger at the New Mexico Consortium found that AI-based protein structure predictions are best considered to be exceptionally useful hypotheses. As good as they are, experimental measurements remain essential when confirming the details of protein structures. #BioMBIB #artificialintelligence #proteinstructure https://lnkd.in/gTdrSNst

What is AlphaFold 3? The AI Model Poised to Transform Biology - AlphaFold 3 is an AI model developed through a collaboration between Google DeepMind and Isomorphic Labs. This groundbreaking technology, which has garnered a lot of attention over the past couple of days as deserved, has achieved an unprecedented capability – accurately predicting the structure and interactions of all life's molecules. This remarkable feat holds the potential to transform our understanding of the biological world and pave the way for profound discoveries across various fields. Revealing the Intricacies of Molecular Structures At its core, AlphaFold 3 possesses the remarkable ability to model the complex structures of large biomolecules that form the […] - https://lnkd.in/eTdR-_dY

Thoughts on the AlphaFold 3 Controversy Nature's editorial today (https://lnkd.in/e4MD5FZB) regarding its decision to publish Google DeepMind and Isomorphic Labs' paper on the AlphaFold 3 release earlier this month, raises interesting points. Read the AlphaFold paper here: https://lnkd.in/eP3CSr3P It is clear that we are in the midst of a true revolution. AlphaFold 3's ability to now predict interactions of biological molecules is an incredible breakthrough. Yet, the lack of immediate code availability nonetheless raises questions about transparency and reproducibility in AI research. I think that Nature's decision, which falls within the guidelines and discretion of their editors also takes into account the interests of all parties. The editorial mentions that the publication will be updated when the code is made available in 6 months. We will surely discuss these topics on the "AI in Healthcare" panel in which I will represent GENOSKIN and participate during the Biotechnology Innovation Organization convention in San Diego. ➡️ Where & When: San Diego Convention Center Corporation Booth #3823 | June 3rd, 2.00-2.45 PM What are your thoughts on the balance between encouraging scientific breakthroughs and ensuring transparency in AI research? I look forward to exchanging on the innovative ways AI is transforming Healthcare. If you're attending, let's connect. ➡️ Schedule a meeting: https://lnkd.in/eW4nXpk9 See you in sunny San Diego! ☀️ #BIO2024 #AI #AlphaFold3 #OpenScience #Innovation #Revolution Business France SoCal French-American Chamber of Commerce ▶ Stephane Richard Bettina ExpertonSteve LevineJean-Frederic Petit-Nivard Brian Atwood Sylvie ALMERI Camille Risso Jerome Revole Nam-Hee LEE

What is AlphaFold 3? The AI Model Poised to Transform Biology - AlphaFold 3 is an AI model developed through a collaboration between Google DeepMind and Isomorphic Labs. This groundbreaking technology, which has garnered a lot of attention over the past couple of days as deserved, has achieved an unprecedented capability – accurately predicting the structure and interactions of all life's molecules. This remarkable feat holds the potential to transform our understanding of the biological world and pave the way for profound discoveries across various fields. Revealing the Intricacies of Molecular Structures At its core, AlphaFold 3 possesses the remarkable ability to model the complex structures of large biomolecules that form the […] - https://lnkd.in/eTdR-_dY

📌 Bringing even more handpicked content and opportunities for collaboration, Oxford Global's NextGen Omics 2023's Track Five on Day One is another opportunity to stay on the forefront of multi-omics research. Dedicated to "Synthetic Biology Tools for Drug Discovery, AI/ Machine Learning, & Computational Approaches", the track starts with the keynote address "Bactobio: How We Use Synthetic Biology, Machine Learning, & Next Generation Sequencing to Find New Drugs" with Mark Wilkinson, Co-Founder and Chief Scientific Officer, Bactobio. You will also have the opportunity to hear from synthetic biology specialists from the Università di Trento, Tel Aviv University, AstraZeneca, University of Nebraska Medical Center, and the Imperial College London on: ▶ Emerging next-gen genomic medicines technologies ▶ AI/ML: » Drug optimisation and discovery » DNA design » Integration of synthetic biology ▶ Artificial cells ▶ Synthetic biology to engineer living cells » CRISPR research for use in synthetic biology » Automated design of RNA circuits in living cells 📖 See the full agenda: https://hubs.la/Q01-9xnr0 🎫 Don't miss out: https://hubs.la/Q01-9Hpj0 #OmicsSeries23 #NextGenOmics2023 #SyntheticBiology #DrugDiscovery #AI #MachineLearning #ComputationalApproaches #NGS #NextGenSequencing #NextGenerationSequencing

📌 Bringing even more handpicked content and opportunities for collaboration, NextGen Omics 2023's Track Five on Day One is another opportunity to stay on the forefront of multi-omics research. Dedicated to "Synthetic Biology Tools for Drug Discovery, AI/ Machine Learning, & Computational Approaches", the track starts with the keynote address "Bactobio: How We Use Synthetic Biology, Machine Learning, & Next Generation Sequencing to Find New Drugs" with Mark Wilkinson, Co-Founder and Chief Scientific Officer, Bactobio. You will also have the opportunity to hear from synthetic biology specialists from the Università di Trento, Tel Aviv University, AstraZeneca, University of Nebraska Medical Center, and the Imperial College London on: ▶ Emerging next-gen genomic medicines technologies ▶ AI/ML: » Drug optimisation and discovery » DNA design » Integration of synthetic biology ▶ Artificial cells ▶ Synthetic biology to engineer living cells » CRISPR research for use in synthetic biology » Automated design of RNA circuits in living cells 📖 See the full itinerary: https://hubs.la/Q01-9H9h0 🎫 Don't miss out: https://hubs.la/Q01-9x030 #OmicsSeries23 #NextGenOmics2023 #SyntheticBiology #DrugDiscovery #AI #MachineLearning #ComputationalApproaches #NGS #NextGenSequencing #NextGenerationSequencing

Creating a digital twin of the human body ... that's the ultimate goal for a lot of people working in drug discovery, and AI is making such a dream possible now, or at least reachable. But like in all other fields where AI promises wonders, what's sorely needed is the relevant data management to make use of all data, experiments and trials that happened in the past and are happening now. Creating a framework for this is a must have, but also a complex endeavour... #drugdiscovery #ai #artificialintelligence #pharma Revolutionizing Bioscience Research: Creating an Atlas of the Human Body - insideBIGDATA

More than 100 researchers, including a Nobel laureate, are calling for the scientific community to prioritize safety and security standards when utilizing artificial intelligence to design synthetic proteins. This call to action is being unveiled today at Winter RosettaCon 2024 in Boston, during a conference dedicated to biomolecular engineering. The statement follows an AI safety summit held last year by the Institute for Protein Design at the University of Washington School of Medicine. By advocating for responsible development of AI for protein design, these researchers are taking a critical step towards ensuring that this technology is developed ethically and safely. #ai #aiadoption #research #techtalks

NIH :: Bridge2AI :: Cell Maps for AI (CM4AI) program #bridge2ai #cm4ai